New drug aims to boost blood counts in rare pre-cancer condition
NCT ID NCT06240754
First seen Feb 13, 2026 · Last updated May 20, 2026 · Updated 14 times
Summary
This study tests a drug called enasidenib in 15 people with clonal cytopenia of undetermined significance (CCUS) who have a mutation in the IDH2 gene. CCUS causes low blood cell counts and can raise the risk of blood cancers. The drug blocks the faulty protein made by the mutated gene, which may help improve blood counts. The study is done mostly at home (decentralized) to make it easier for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.